Quarterly report pursuant to Section 13 or 15(d)

Segment Reporting - Net Revenue and Operating Profit of Each Segment (Detail)

v3.5.0.2
Segment Reporting - Net Revenue and Operating Profit of Each Segment (Detail) - USD ($)
 3 Months Ended 9 Months Ended
Aug. 31, 2016
Aug. 31, 2015
Aug. 31, 2016
Aug. 31, 2015
Nov. 30, 2015
Segment Reporting Information [Line Items]          
Total net revenue $ 6,331,938 $ 5,435,990 $ 17,257,192 $ 15,293,260  
Total cost of sales 1,551,231 1,507,393 4,330,622 4,158,767  
Total depreciation and amortization 39,746 25,359 123,166 60,702  
Total operating income (1,062,075) 1,264,316 (23,269) 2,491,598  
Total interest expense 199,439 $ 353,534 804,236 $ 1,024,621  
Total assets 17,542,285   17,542,285   $ 19,497,946
Umbilical Cord Blood and Cord Tissue Stem Cell Service [Member]          
Segment Reporting Information [Line Items]          
Total net revenue 6,243,803   16,970,939    
Total cost of sales 1,482,900   4,073,293    
Total depreciation and amortization 27,310   84,542    
Total operating income 808,254   1,864,325    
Total interest expense 199,439   781,971    
Total assets 16,755,419   16,755,419   16,697,621
Prepacyte CB [Member]          
Segment Reporting Information [Line Items]          
Total net revenue 88,135   286,253    
Total cost of sales 68,331   257,329    
Total depreciation and amortization 12,436   38,624    
Total operating income (1,870,329)   (1,887,594)    
Total interest expense     22,265    
Total assets $ 786,866   $ 786,866   $ 2,800,325